Health Care Equipment & Services

Insider buying at AngioDynamics signals confidence, with execs boosting shares amid revenue growth and a bullish outlook for vascular tech.

Agwunobi John O’s routine sale of 392 Ensign Group (ENSG) shares at $171.06 shows a steady, non‑market‑reactive strategy, signaling long‑term confidence in the company’s health‑care trajectory.

Analyze SOPHiA Genetics’ July insider trades and market context – discover how disciplined 10‑b‑5‑1 actions reflect investor confidence and future growth opportunities in genomic analytics.

Insider buy of 26,655 OMADA Health shares signals board confidence, as clinical trials show 5‑7% weight loss and 0.6‑0.8% HbA1c reduction with safe, FDA‑supported digital care.

Guardant Health insider buying by Hidalgo Medina shows confidence amid volatile prices and a BBB credit upgrade—what this means for investors.

Insider selling spikes at Cerus Corp reveal the CEO’s strategy amid a 121% year‑to‑date gain and a high‑risk biotech focus on pathogen‑inactivation technology.

Insider buying at Inspire Medical Systems signals confidence—director Melenikiotou’s 344‑share purchase boosts investor interest ahead of the next funding round.

Insight into HEARTFLOW’s leadership trading: CEO Rogers Campbell buys near the 52‑week low and sells at a modest premium, showing confidence in the AI‑driven coronary platform and offering investors a disciplined view of future valuation potential.

Explore how Clover Health’s CEO’s July 17 insider sale, under a Rule 10b5‑1 plan, balances tax strategy with regulatory thresholds, market sentiment, and Medicare‑advantage growth.

Schrödinger Inc.’s CFO sells 875 shares for $15.60 each—an automated tax‑plan move, not a strategic shift, amid a volatile market and mixed insider buying.